Loading clinical trials...
Loading clinical trials...
A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma
Conditions
Interventions
FACT Complex-targeting Curaxin CBL0137
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
July 1, 2019
Primary Completion Date
January 16, 2024
Completion Date
January 16, 2024
Last Updated
March 27, 2024
NCT05039801
NCT01989585
NCT04462406
NCT03698019
NCT04940299
NCT03554083
Lead Sponsor
Roswell Park Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions